NASDAQ, QNRX #New Clinical Trial Data #Syndromes #Trending News Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial May 24, 2023 08:15 EST ASHBURN, Va., May 24, 2023 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announces that its open label study evaluating QRX003 as a treatment for Netherton Syndrome has reached 50% enrollment. The company’s No Comments
OTC, TRYPF #FDA Application Submitted #Phase 2 #Syndromes Tryp Therapeutics Submits Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical Trial in Patients With IBS at Massachusetts General Hospital May 24, 2023 06:00 EST KELOWNA, BC / ACCESSWIRE / May 24, 2023 / Tryp Therapeutics, Inc. (CSE:TRYP)(OTCQB:TRYPF) (Tryp or the Company), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced it has submitted an Investigational New Drug (IND) application No Comments
OTC, TRYPF #FDA Application Submitted #Phase 2 #Syndromes Tryp Therapeutics Submits Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical Trial in Patients With IBS at Massachusetts General Hospital May 24, 2023 06:00 EST KELOWNA, BC / ACCESSWIRE / May 24, 2023 / Tryp Therapeutics, Inc. (CSE:TRYP)(OTCQB:TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced it has submitted an Investigational New Drug (IND) application No Comments
NASDAQ, RGNX #FDA #Syndromes REGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter Syndrome May 23, 2023 07:05 EST RMAT recognizes that the preliminary clinical evidence from RGX-121, a potential one-time AAV Therapeutic, indicates the potential to address unmet medical needs for MPS II RMAT designation is for gene therapies intended to treat or cure serious condition in order to expedite the drug development and review processes CAMPSIITE™ trial No Comments
NASDAQ, ZYNE #Cannabis #Event #New Clinical Trial Data #Syndromes Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting May 23, 2023 07:00 EST DEVON, Pa., May 23, 2023 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced an oral podium presentation and poster presentations at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP 2023), being held May 30 No Comments
NASDAQ, RDHL #Letter to Shareholders #Syndromes RedHill Provides R&D Update May 22, 2023 07:00 EST RedHill has elected to terminate RHB-204’s U.S. Phase 3 study for Non-tuberculosis Mycobacteria (NTM) disease due to low accrual rate and plans to shift resources to more rapidly advance RHB-107 late-stage development for outpatient treatment of COVID-19 RedHill’s advanced pipeline also includes: Opaganib – in collaboration with the U.S. No Comments
NASDAQ, TSHA #Event #New Clinical Trial Data #Syndromes #Trending News Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26th Annual Meeting May 19, 2023 08:00 EST New preclinical data after neonatal administration in wild-type mice showed no detectable impact on survival, neurobehavioral functions and overall health, suggesting TSHA-102, engineered with novel miRARE technology, avoided toxic overexpression of MeCP2 within cells already expressing MeCP2 Data reinforce previous findings in Mecp2–/Y knockout mice demonstrating TSHA-102 regulated cellular No Comments
ATHX, NASDAQ #Financial Data #Syndromes #Trending News Athersys Reports First Quarter 2023 Financial Results and Business Highlights May 18, 2023 09:58 EST CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced on Monday, May 15th financial results for the three months ended March 31, 2023 and provided a business update. First Quarter 2023 and Recent Corporate and Operational Highlights Continued reducing No Comments
BMRA, NASDAQ #Syndromes #Trending News inFoods® IBS Test Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology May 18, 2023 08:19 EST Gastro Health, a leading gastroenterology group, plans to utilize this simplified blood collection method when recommending the inFoods® IBS to their patients Biomerica also announced that inFoods® IBS clinical trial data was presented at the DDW conference May 8th.The data showed that the inFoods® IBS treatment diet significantly improved No Comments
NASDAQ, RARE #Expansion #FDA #Phase 1/2 #Syndromes #Trending News Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S. May 17, 2023 08:00 EST NOVATO, Calif., May 17, 2023 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) has reviewed and agreed to a protocol amendment to the Phase 1/2 study of GTX-102 in pediatric patients with Angelman syndrome that enables the company to No Comments
Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma 05/26/2023
Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting 05/26/2023
US Investors May Now Have Trading Access for Genius Group Shares on Upstream through US Broker Dealer 05/26/2023
New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn’s Disease 05/25/2023
Shareholder Alert: Ademi LLP investigates whether CohBar, Inc. has obtained a Fair Price in its transaction with Morphogenesis, Inc. 05/24/2023